Core Viewpoint - Company has received approval from the Shandong Provincial Drug Administration to expand its production capabilities, which is expected to positively impact its future operations [1] Summary by Sections Production License Update - The company has been granted permission to add a new workshop and production line for the production of tablets, specifically in the Heze City location [1] - The new workshop added is the Comprehensive Preparation VI workshop, which will focus on tablet production [1] Contract Manufacturing Extensions - The company has extended its contract manufacturing agreements for various products: - Loratadine tablets and Montelukast chewable tablets until July 16, 2028 - Ibuprofen sustained-release capsules and Ezetimibe tablets until July 16, 2028 - Pregabalin capsules until March 31, 2028 - Donepezil hydrochloride tablets until July 7, 2030 [1] Impact on Operations - The changes in the production license, including the addition of workshops and production lines, are expected to optimize the company's production structure [1] - This will help maintain stable production capacity and meet market demand, leading to a positive impact on the company's future operations [1]

Core Viewpoint - Company has received approval from the National Medical Products Administration for the drug "Xiaolinbaituxian," which will enhance product quality and meet market demand, positively impacting future operations [1][2]. Group 1: Drug Approval and Details - The drug "Xiaolinbaituxian" has been approved for marketing, with the original approval number remaining unchanged [1]. - The marketing authorization holder has been changed from "Shandong Kongfu Pharmaceutical Co., Ltd." to "Shandong Buchang Pharmaceutical Co., Ltd." [1]. - The drug is used for clearing heat and detoxifying, particularly for symptoms related to lower urinary tract infections [1]. Group 2: Research and Development Investment - The company has invested approximately 28.15 million RMB in research and development for "Xiaolinbaituxian" and its pill form [1]. - The company emphasizes the importance of quality and safety in drug research, manufacturing, and sales [2].

Core Points - The controlling shareholder, Buchang (Hong Kong), holds 490,957,202 shares, accounting for 46.56% of the total share capital of the company [1] - A total of 100,930,000 shares have been pledged by Buchang (Hong Kong), representing 20.56% of its holdings and 9.57% of the company's total share capital [1] - Together with its concerted parties, Buchang (Hong Kong) holds 598,200,660 shares, which is 56.72% of the total share capital, with 100,930,000 shares pledged [1] - The pledged shares do not serve as collateral for major asset restructuring or performance compensation [2] - Buchang (Hong Kong) has sufficient risk control capabilities and repayment ability, with sources of repayment including operating income, operating profit, and investment income [3] - There is currently no risk of forced liquidation, and measures such as supplementary pledges or early repurchase of pledged shares will be taken if necessary [3] - The pledge will not lead to a change in actual control of the company or affect its operations and governance [4]

Group 1 - The company announced that its controlling shareholder, Bichang (Hong Kong) Holdings Limited, has completed a share pledge procedure involving 11,000,000 shares [1]

Group 1 - The core point of the news is that the controlling shareholder of Buchang Pharma, Buchang (Hong Kong), holds approximately 491 million shares, accounting for 46.56% of the total share capital, and has pledged about 101 million shares, which is 20.56% of its holdings and 9.57% of the total share capital [1] - The total shares held by Buchang (Hong Kong) and its concerted parties amount to approximately 598 million shares, representing 56.72% of the total share capital, with a total of 101 million shares pledged, which is 16.87% of their holdings and 9.57% of the total share capital [1] - For the year 2024, the revenue composition of Buchang Pharma is 99.71% from the pharmaceutical industry and 0.29% from other businesses [1] Group 2 - As of the report, Buchang Pharma has a market capitalization of 18.6 billion yuan [2]

证券代码：603858 证券简称：步长制药 公告编号：2025-210 山东步长制药股份有限公司 关于控股股东股份质押的公告 | | | | | | | | | 比例 | 比例 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | （%） | （%） | | | 步长（香港） | | | | | | | 中国光大 | | | | | | | | | | | | 银行股份 | | | | | 控股有限公 | 是 | 11,000,000 | 否 | 否 | 2025.11.7 | 2028.11.6 | 有限公司 | 2.24 | 1.04 | 经营所需 | | 司 | | | | | | | | | | | | | | | | | | | 济南分行 | | | | 2、本次质押股份未被用作重大资产重组、业绩补偿等事项的担保或其他保 障用途。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ...

Core Viewpoint - On November 7, 2025, the company announced the approval of a change in the business scope of its wholly-owned subsidiary, Yangling Buchang Pharmaceutical Co., Ltd., during the 35th meeting of the fifth board of directors, which was held via telecommunication [1]. Group 1 - The board meeting received a unanimous vote with 8 votes in favor, 0 against, and 0 abstentions [1]. - The change in business scope is driven by the operational management needs of the subsidiary [1].

证券代码：603858 证券简称：步长制药 公告编号：2025-209 山东步长制药股份有限公司 关于全资子公司经营范围变更的公告 变更后经营范围：中药提取物生产；医学研究和试验发展；非居住房地产租 赁；太阳能发电技术服务。（除依法需经批准的项目外，凭营业执照依法自主开 展经营活动）。许可项目：药品生产；药品委托生产；药品进出口；药品批发（依 法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以审批 结果为准）。 以上经营范围变更最终以工商部门核准信息为准。 二、主要财务数据 截至 2024 年 12 月 31 日，资产总额 109,196.14 万元，负债总额 117,618.21 万元，净资产-8,422.06 万元，2024 年度实现营业收入 19,903.42 万元，净利润 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 10 月 31 日发 出第五届董事会第三十五次会议的通知，并于 2025 年 11 月 7 日 13 时以通讯方 式召开 ...

山东步长制药股份有限公司 2025 年第一次临时股东会会议资料 中国·菏泽 2025 年 11 月 17 日 山东步长制药股份有限公司 2025年第一次临时股东会文件目录 一、会议须知 二、会议议程 三、会议议案 （一）关于公司取消监事会、调整董事会人数的议案； （二）关于修订《山东步长制药股份有限公司章程》的议案； （三）关于修订《山东步长制药股份有限公司股东会议事规则》 的议案； （四）关于修订《山东步长制药股份有限公司董事会议事规则》 的议案； （五）关于修订公司部分治理制度的议案； （六）关于补选公司第五届董事会独立董事的议案； （七）关于补选公司第五届董事会非独立董事的议案。 四、附件 议案二附件：《山东步长制药股份有限公司章程（2025 年 10 月 修订）》 议案三附件：《山东步长制药股份有限公司股东会议事规则 （2025 年 10 月修订）》 议案四附件：《山东步长制药股份有限公司董事会议事规则 1 （2025 年 10 月修订）》 议案五附件： 附件 1：《山东步长制药股份有限公司重大交易决策制度（2025 年 10 月修订）》 附件 2：《山东步长制药股份有限公司对外投资决策制度（2025 ...

Core Viewpoint - The company reported a revenue of 8.469 billion yuan for the first three quarters of 2025, a slight decrease of 0.54% year-on-year, while net profit attributable to shareholders increased by 177.54% to 868 million yuan, demonstrating resilience through product innovation, international expansion, and technological upgrades [1] Group 1: Business Performance - The company achieved a revenue of 8.469 billion yuan in the first three quarters of 2025, reflecting a year-on-year decline of 0.54% [1] - Net profit attributable to shareholders reached 868 million yuan, marking a significant increase of 177.54% year-on-year [1] - Basic earnings per share were reported at 0.8208 yuan [1] Group 2: Product and Market Expansion - The company is expanding into the biopharmaceutical and vaccine sectors, with significant developments in product pipelines, international markets, and technological innovation [2] - A new product, ibuprofen sustained-release capsules, received approval from the National Medical Products Administration, enhancing the company's product line in the analgesic field [2] - The company’s core product, adalimumab injection, is under review for market approval, with projected sales of 2.2 billion yuan in China by 2024 [2] Group 3: International Collaboration - The company signed an exclusive supply agreement with GOODFELLOW in the Philippines for the injection of Efparepoetin alfa, aimed at treating anemia in chronic kidney disease patients [3] - An exclusive distribution agreement was also signed with Helios in Vietnam for the same product, indicating a strategic move in the international market [3] Group 4: Vaccine Development - The company achieved dual breakthroughs in the vaccine sector, receiving approval for a quadrivalent influenza vaccine and advancing clinical trials for a varicella vaccine [4] - The vaccine pipeline now includes multiple products targeting various diseases, solidifying the company's position in preventive medicine [4] Group 5: Technological Advancements - The company has integrated AI into traditional Chinese medicine, enhancing production and quality control processes [4] - It was recognized as a "2024 Pharmaceutical Intelligent Manufacturing Demonstration Factory," showcasing its commitment to innovation and sustainability [4] Group 6: Quality Management - The company’s subsidiary successfully passed ISO certifications for quality, environmental, and occupational health management systems, ensuring compliance with international standards [5] Group 7: Social Responsibility - The company has been actively involved in public welfare initiatives, particularly in providing medical assistance to underprivileged communities, demonstrating its commitment to social responsibility [6][7] - Since 2008, the company has supported over 50,000 individuals through its charitable programs, including free surgeries for children with congenital heart disease [6][7] Group 8: Economic Contributions - The company has contributed over 32 billion yuan in taxes since its establishment, supporting local infrastructure and public services [7] - It has maintained a stable dividend policy, distributing nearly 7.948 billion yuan in dividends since its IPO, reflecting its commitment to shareholder returns [7]